Evidence map›Paper›PMID 42616072›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Asundexian 50 mg for stroke prevention: a systematic review and meta-analysis of 14,031 patients.

Omar Fayez Abbas, Radhika Amin, Sherief Ghozy, Abdelrahman M Hamouda, Roaa Haddad, R Saha, Ram Kadrivel, David F Kallmes

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Omar Fayez AbbasFaculty of Medicine, Al-Azhar University, Cairo, Egypt. omarfayez0007@gmail.com.
Radhika AminSchool of Medicine, District of Columbia, Georgetown University, Washington, USA.
Sherief GhozyDepartment of Radiology, Rochester, MN, 55904, USA.
Abdelrahman M HamoudaDepartment of Neurologic Surgery, Rochester, MN, 55904, USA.
Roaa HaddadFaculty of Medicine, October 6 University, Cairo, Egypt.
R SahaVirginia Commonwealth University SOM, Richmond, VA, USA.
Ram KadrivelDepartment of Neurologic Surgery, Rochester, MN, 55904, USA.
David F KallmesDepartment of Radiology, Rochester, MN, 55904, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asundexian, a novel oral factor XIa inhibitor, may prevent thrombosis without increasing bleeding. We evaluated its efficacy for stroke prevention in high-risk patients. We systematically searched PubMed, Scopus, Cochrane, and Web of Science through March 2026 for randomized controlled trials comparing asundexian 50 mg daily versus placebo for secondary stroke prevention. Primary outcomes were ischemic stroke, any stroke, and all-cause mortality. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using random-effects models. Three trials comprising 14,031 patients were included. Asundexian significantly reduced ischemic stroke (RR 0.74, 95% CI 0.63-0.88; p = 0.01; I

Indexed as

Asundexian 50 mgFactor XIaStroke

Identifiers

PMID42616072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.